Valvular & structural heart disease
Estimating the Effects of Mitral Transcatheter Edge-to-edge Repair (MTEER) in U.S. Practice: A Transportability Analysis of the COAPT Trial
Primary result · HF hospitalization, trial-eligible populationResult — go to the resultAbsolute risk reduction 17.0% 95% CI −28.7% to −5.7%Authors' conclusion
Although COAPT trial patients had different baseline characteristics than patients undergoing MTEER in contemporary U.S. practice, we estimated that treatment effects would be similar had real-world patients received COAPT trial interventions, under the assumptions required for transportability (eg, conditional exchangeability across data sources, positivity of trial participation).
Study context
- Population
- Patients treated with MTEER for secondary mitral regurgitation, STS/ACC Transcatheter Valve Therapy (TVT) Registry, March 14, 2019 to September 30, 2023; trial-eligible and treatment-candidate target populations614 COAPT + 15,275 TVT Registry patients
- Comparison
- MTEER plus COAPT interventions vs medical therapy alone
- Primary endpoint
- HF hospitalization
- Follow-up
- 2 years
Methodological detailsinverse odds of participation weighting, TVT Registry
- Inverse odds of participation weighting
- TVT Registry
Primary result
HF hospitalization, trial-eligible population
Absolute risk reduction
17.0%
95% CI −28.7% to −5.7%
As reported in the abstract
Secondary outcomes
| Outcome | Absolute risk reduction (95% CI) |
|---|---|
| All-cause death, trial-eligible population · 2 years · similar to trial (P for difference >0.05) | 15.4% (−26.6% to −5.2%) |
HF hospitalization, treatment-candidate population
- Treatment effect similar to that in the COAPT trial
- P for difference = 0.90
Original publication
Estimating the Effects of MTEER in U.S. Practice: A Transportability Analysis of the COAPT Trial. J Am Coll Cardiol. Published 3 June 2026. doi:10.
Summarised from the published abstract; every number is checked against it